A Strong Impulse for Future Cancer Treatments

Leiden, June 17 – The early-stage investment fund UNIIQ has made a strategic investment in GenLumina, a promising biotech startup developing groundbreaking technology for cancer treatment using silver and light. This investment marks a significant milestone for GenLumina and underscores confidence in both the potential of the technology and the strength of the team.

“This investment enables us to conduct a preclinical study on the safety and efficacy of our patented drug, while also expanding the application of our technology to other therapeutic domains,” says Gerco Kanbier, CEO of GenLumina.

Looking Ahead

With this financial injection, GenLumina can accelerate its development efforts and attract strategic partners for the next phase. The ambition is clear: to make safe, light-activated cancer therapies available to patients worldwide.

About GenLumina

GenLumina is a spin-off from Leiden University, developing innovative cancer therapies that use light as a precision tool to destroy tumor cells from within. The technology integrates nanomedicine, optics, and molecular biology for maximum effectiveness with minimal side effects.

About UNIIQ

UNIIQ is an early-stage investment fund that helps entrepreneurs bridge the critical gap from concept to proof. The fund focuses on innovative companies in the South Holland region and is an initiative of TU Delft, Erasmus MC, Leiden University, and InnovationQuarter.